Table 2. Patient Histological Data and chemotherapy regime.
| Patient No. | Age | Lymph nodes | Tumor Type | Grade | ER status | PR status | HER 2 Status | NACT Regime |
|---|---|---|---|---|---|---|---|---|
| 1 | 58 | - | Ductal NST | 2,3 | - | - | + | 4×EC + 4×DC |
| 3 | 40 | + | Ductal NST | 2 | + | - | + | 2×EC + 4×DC |
| 4 | 47 | - | Ductal NST | 2 | + | + | + | 6×EC |
| 5 | 40 | + | Ductal NST | 2 | + | + | - | 4×EC + 2×DC |
| 6 | 49 | + | Ductal/Lobular | 1 | + | + | - | 2×EC + 6×DC |
| 7 | 50 | - | Ductal NST | 3 | - | - | - | 4×EC + 4×DC |
| 8 | 42 | + | Ductal NST | 2 | + | + | - | 3×DC + 3×FEC |
| 9 | 47 | + | Ductal NST | 3 | + | - | - | 3×DC |
| 10 | 50 | - | Ductal NST | 2 | + | + | - | 3×EC + 4×DC |
| 11 | 61 | + | Ductal NST | 3 | + | - | + | 4×EC + 4×DC |
| 12 | 42 | + | Ductal NST | 2 | + | + | - | 4×EC + 4×DC |
| 13 | 45 | + | Ductal NST | 3 | - | - | - | 4×EC + 4×DC |
| 14 | 54 | + | Ductal NST | 3 | - | - | + | 4×EC + 3×DC |
| 15 | 61 | + | Ductal NST | 3 | - | - | - | 4×EC + 4×DC |
| 16 | 60 | + | Basal Features | 3 | - | - | - | 4×EC + 4×DC |
| 17 | 38 | + | Ductal NST | 2 | + | - | + | 2×EC + 4×DC |
| 18 | 53 | + | Ductal NST | 2,3 | + | - | - | 3×EC + 4×DC |
| 20 | 40 | + | Ductal NST | 3 | + | - | - | 4×EC + 2×DC |
Ductal NST: ductal carcinoma of no specific type, ER: estrogen receptor, PR: progesterone receptor, HER 2: human epidermal growth factor receptor 2, EC: epirubicin & cyclophosphamide, DC: docetaxel & cisplatin, FEC: fluorouracil & EC.